The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)
Biology of Blood and Marrow Transplantation（2004）
关键词
radioimmunotherapy,dose 90yttrium ibritumomab tiuxetan,lymphoma,novel transplant regimens,autologous stem cell transplantation,y-zevalin,b-cell,non-hodgkin
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要